Moderna revenue fell 39.9% to $1.9B in FY with -145.2% net margin
Moderna tumbled in today's session as the company continues to post deeply negative margins on sharply declining revenue, with FY revenue down ~40% YoY to $1.9B and a net margin of -145%. The setup pits a potential pipeline catalyst against a structurally deteriorating top line with no clear path to profitability in the near term.
The story
Moderna fell sharply in today's trading session, continuing a broader downtrend driven by fundamental deterioration. FY revenue came in at $1.9B — a steep 39.9% decline year-over-year — while the company's net margin sits at a deeply negative -145.2%, translating to a diluted EPS loss of $7.26. The COVID vaccine cycle that once powered Moderna's financials has clearly wound down, and replacement revenue from new products has not yet materialized at meaningful scale.
The numbers paint a picture of a company in a post-peak transition phase. With no profitability in sight and cash burn accelerating, investors face a binary question: does Moderna's pipeline — particularly its mRNA flu vaccine and RSV candidates — represent a legitimate second act, or is the market overestimating the timeline and commercial potential of these programs?
The bear case is straightforward: revenue is collapsing, losses are widening, and there is no near-term catalyst that reverses the top-line trajectory. Competing RSV and flu products from larger, better-capitalized players (Pfizer, GSK) add commercial headwinds.
The bull case rests on mRNA platform optionality — Moderna's pipeline spans oncology, rare disease, and respiratory, and a single Phase 3 readout could re-rate the stock. Cash on the balance sheet has historically provided a runway buffer, though that cushion is being consumed rapidly at current burn rates.
What to watch: any clinical readout on the mRNA-1345 (RSV) or flu programs, quarterly cash burn updates, and whether management revises guidance further. The next earnings print will be the key near-term catalyst.
Our read · Fri, Jul 10
MRNA faces a tension between pipeline optionality on the mRNA platform and a structurally collapsing revenue base — the question is whether any near-term clinical catalyst can outweigh the pace of cash burn and top-line erosion.
Why. Revenue is down ~40% YoY to $1.9B with a -145% net margin and -$7.26 EPS — fundamentals are deteriorating faster than the pipeline can offset. There is no near-term approved product to reverse the top-line decline, and cash burn continues to accelerate without a clear profitability path. Today's tumble suggests the market is re-rating toward fundamentals rather than pipeline optionality.
Both cases
What could change this view: A surprise positive Phase 3 readout on mRNA-1345 (RSV) or the flu vaccine program could trigger a sharp short squeeze; any M&A rumor or licensing deal would also invalidate the short thesis quickly.
Who reported it · 1
Keep reading
More on MRNA
Moderna swings to profit as cancer-vaccine momentum gathers paceModerna cancer vaccine cuts melanoma recurrence or death by 42%Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage TrialModerna shares surge 179% on melanoma therapy; revenue fell 39.9% to $1.9BLatest on the Wire
Walmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandContinue on the Wire →Latest on the Wire
Trump, Xi and Putin pledge more refined fuel after first trilateral summitSky reserve linked to $518 million in illicit activity, investigation findsBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%UniCredit reaches agreement with Berlin over Commerzbank takeoverContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic Said to Guide IPO Pricing Above Market RangeNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by Yahoo Finance as Stock Market Today: Dow Ends Higher; SK Hynix Jumps In U.S. Trading Debut; Moderna Tumbles
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →